CEACAM6 and urinary bladder carcinoma: Since previous studies have suggested that CEACAM6 could be a potential target for different cancer immunotherapies (Han et al. 2020), our evidences further highlighting its role as both a prognostic and a therapeutic target in bladder cancer.